FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple ...

US subsidiary and Iceland-based Alvotech (Nasdaq: ALVO) today announced that the US Food and Drug Administration (FDA) has ...

The share price of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) is rising sharply after the company reported ...

The drug has been chosen as the sole ustekinumab by BCBSM, Florida Healthcare Plan, and other closed-door health systems.

Shares of Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA) surged 6.2% while Alvotech SA (NASDAQ: ALVO) climbed 3.5% in ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access ...

Amgen AMGN is off to a strong start in 2025 with its first-quarter earnings as well as sales beating estimates. Particularly, ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , and Alvotech today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDItm (ustekinumab-aekn) ...

The U.S. FDA has approved SELARSDI (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Biocon Biologics secures market access for Yesintek in the US driven by demand from national and commercial formularies: Our Bureau, Bengaluru Monday, May 5, 2025, 12:15 Hrs [IST] ...